menu
    • menu
    [{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Ridinilazole","moa":"Cell Division","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios SA","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios SA"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Eurofarma Laboratorios S.A \/ Eurofarma","highestDevelopmentStatusID":"12","companyTruncated":"Eurofarma Laboratorios S.A \/ Eurofarma"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eurofarma Laboratorios S.A","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Eurofarma","highestDevelopmentStatusID":"12","companyTruncated":"Eurofarma Laboratorios S.A \/ Eurofarma"}]

    Find Clinical Drug Pipeline Developments & Deals by Eurofarma Laboratorios S.A

    Menu

    Eurofarma Laboratorios S.A

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eurofarma Laboratorios S.A

                            Brazil arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eurofarma Laboratorios S.A

                            Brazil arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : SK Biopharmaceuticals

                            Deal Size : $62.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin America

                            Details : Under the terms of agreement, SK Biopharmaceuticals has granted Eurofarma the exclusive rights to develop and commercialize Xcopri (cenobamate) in Latin America. SK Biopharmaceuticals will now be present in four continents: North America, Europe, Asia, a...

                            Brand Name : Xcopri

                            Molecule Type : Small molecule

                            Upfront Cash : $15.0 million

                            July 14, 2022

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : SK Biopharmaceuticals

                            Deal Size : $62.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eurofarma Laboratorios S.A

                            Brazil arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eurofarma Laboratorios S.A

                            Brazil arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Pacira BioSciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Pacira BioSciences Signs Exparel Distribution Agreement With Eurofarma in Latin America

                            Details : Under the terms of the agreement, Eurofarma obtains the exclusive right to market and distribute EXPAREL in 19 countries in Latin America, including Argentina, Brazil, Colombia, and Mexico.

                            Brand Name : Exparel

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 22, 2021

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Pacira BioSciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eurofarma Laboratorios S.A

                            Brazil arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eurofarma Laboratorios S.A

                            Brazil arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ridinilazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Summit Therapeutics

                            Deal Size : $3.8 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Summit Therapeutics to Receive $1.0 Million Milestone Payment

                            Details : The milestone payment was initiated by Summit achieving its initial patient enrolment target at trial sites in Latin America in the Phase 3 clinical trials of ridinilazole for C. difficile infection.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 06, 2020

                            Lead Product(s) : Ridinilazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Summit Therapeutics

                            Deal Size : $3.8 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth